NCT04086758View on ClinicalTrials.gov

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Interventions
DRUG

zolbetuximab

Zolbetuximab will be administered as a 2-hour intravenous infusion

Trial Locations (1)

Unknown

Site CN86001, Guangzhou

All Listed Sponsors
lead

Astellas Pharma China, Inc.

INDUSTRY

NCT04086758 - A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Biotech Hunter | Biotech Hunter